N1-(benzenesulfonyl)-n-(tetrahydro-thiapyranyl)ureas



United States Patent 9 Claims. Ci. 260-327) ABSTRACT OF THE DISCLIJSURE The invention involves N (benzenesulfonyl) N (terahydro thiaphranyl)ureas useful as oral antidiabetic activity.

This is a continuation of our copending application Ser. No. 411,585, filed Nov. 16, 1964, now abandoned.

This invention relates to a series of new benzenesulfonylureas having utility as antidiabetie agents. More particularly, this invention relates to benzenesulfonylureas in which the N substituent consists of a tetrahydrothiapyrane radical. It is known that various benzenesulfonylureas have blood sugar reducing properties and are suitable as oral antidiabetic agents (see, for example, "Arzneimittel-Forschung, vol. 8, pp. 44-8-454 (1958)). In particular, N sulfanilyl N (n butyl) urea and N (4 methylbenzenesulfonyl) N (n butyl) urea have acquired great importance in the treatment of diabetes.

In German Patent 1,011,413 benzenesulfonylureas are described substituted by an open chain or cyclic hydrocarbon radical containing hetero atoms on the N atom, as, for instance, alkylrnercaptoalkyl radicals. These compounds are less toxic than compounds which contain no hetero atoms. However, their antidiabetic effectiveness is also poor.

It has now surprisingly been discovered that benzenesulfonylureas having as the N substituent a tetrahydrothiapyrane radical constitute superior antidiabetic compounds having very great blood sugar reducing activity, while their toxicity is just as low or lower than that of the above named compounds of German Patent No. 1,011,413. In view of the strong antidiabetic action and little or no incidence of undesirable side effects, the new compounds can be administered over a broad therapeutic range, such as has seldom, if ever, been achieved with compounds of the sulfonyl series.

The compounds of this invention have the following structural formula:

and the salts thereof, wherein R and R represent hydrogen, halogen, alkyl, alkenyl, alkoxy, alkenoxy, alkylmercapto, acyl, azido, cyano, trifluoromethyl, an amino group or a group which may be converted into an amino group.

The term salts as used herein is intended to include all non-toxic or pharmacologically-acceptable alkali, alkaline earth and ammonium salts. Such salts are easily prepared by methods known to the art.

The compounds of this invention are prepared by the methods conventionally used for the synthesis of substituted ureas;

See

(a) Reaction of benzenesulfonyl compounds of the formula:

with compounds of the formula:

In the above formulae, one of the radicals Z and U represents an amino group while the other is an isocyanate group or a radical which gives rise to an isocyanate group under the conditions of the reaction.

Thus, for example, a sulfonylisocyanate can be reacted with 4 amino tetrahydrothiapyrane or an acyl derivative thereof, or, alternatively, a sulfonamide (preferably in the form of its sodium or potassium salt) is condensed with tetrahydrothiapyrane isocyanate former. An isocyanate former is understood to mean a compound which, under the conditions of reaction, is capable of conversion into an isocyanic acid ester as, for example, carbamic acid halides, urethanes, thiourethanes, ureas and their acyl derivatives and disulfonylureas.

(b) Hydrolysis of benzenesulfonylthioureas or benzenesulfonylguanidines or benzenesulfonylisourea ethers 0 alkyl with ureas of the formula wherein R and R are as above defined. In this latter method it is advantageous to employ, in place of the tetrahydrothiapyranylureas, the corresponding parabanic acid derivatives I HN N H S The following examples are drawn to illustrate the novel compounds of this invention and will serve to illustrate the process for the preparation of the compounds.

EXAMPLE 1 5.3 g. 4-methoxybenzenesulfonyl-methylurethane were mixed with a solution of 2.5 g. 4-amino-tetrahydrothiapy- 3 rane in 50 ml. toluene. After dissolution was complete, the solution was heated for 2 hours at 120 C., and at the same time the alcohol which formed during the reaction was distilled oif. The solution was then cooled and the concentrate was dissolved in dilute sodium bicarbonate solution. The resulting solution was filtered through charcoal and the N -(p-methoxy-benzenesulfonyl)-N (tetrahydrothiapyranyl-4)-urea separated by precipitation with dilute hydrochloric acid. Yield: 85%, M.P. 204- 206 C.

Analogously, the following compounds were produced: N (p-toluenesulfonyl)-N -(tetrahydro-thiapyranyl-4)- urea M.P. 209-210" C.

N (p-chloro-benzenesulfonyl)-N -(tetrahydrothiapyranyl-4)-urea, M.P. 206 C.

EXAMPLE 2 7.3 g. 4-chloro 3 acetamino-benzenesulfonyl-methylurethane and 2.8 g. 4-amino-tetrahydro-thiapyrane were dissolved in 75 cc. absolute toluene. The solution was then heated for 2 /2 hours at 1101l5 C. and the alcohol which formed was separated cit by distillation. After cooling, the precipitated N -(4-chloro-3-acetamino-benzenesulfonyl)-N -(tetrahydrothiapyranyl-4)-urea was recovered by suction filtering and washed with ether. Yield: 96%, M.P. 175-177 C.

EXAMPLE 3 9 g. N (3 acetamino-4-chloro-benzenesulfonyl)-N (tetrahydrothiapyranyl-4)-urea which had been obtained according to Example 2 were dissolved in 35 cc. of 2 N caustic soda solution and the resulting solution heated for 1 hour on the vapor bath. Following neutralization of the alkaline solution, the N -(3-amino-4-chloro-benzenesulfonyl) N (tetrahydrothiapyranyl-4)-urea precipi tated out. The N -(3-amino-4-chlorobenzenesulfonyl)- N -(tetrahydrothiapyranyl)-4-urea was purified by recrystallization from alcohol. Yield 93%, M.P. 192- 194 C.

EXAMPLE 4 2.6 g. p-acetyl-benzenesulfonyl-methylurethane were heated in 30cc. absolute toluene with 1.2 g. 4-amino-tetrahydrothiapyrane for 3 hours at 110l20 C. The alcohol which formed during the reaction was distilled off. After completion of the reaction the precipitate was separated by suction filtering and washed with ether. The washed precipitate was dissolved in dilute sodium bicarbonate solution, any slight residue was filtered out and the filtrate treated with dilute hydrochloric acid. In this manner, N (p acetyl-benzenesulfonyl)-N -tetrahydrothiapyranyl-4)-u1'ea was obtained, in a 76% yield, M.P. 195- 197 C. In an analogous manner N (p-isopropyl-benzenesulfonyl) N (tetrahydrothiapyranyl-4)-urea was prepared, M.P. 201-202 C.

The end products of this process may be combined with a pharmaceutical carrier for administration to humans in an amount to attain the desired antidiabetic effect. Such carriers are either solid or liquid. Exemplary of solid pharmaceutical carriers are lactones, cornstarch, manitol, talc, etc. The compounds of this invention are mixed with a carrier and filled into hard gelatin capsules or tableted with suitable tableting aids such as magnesium, stearate, starch, or other lubricants, disintegrants or coloring agents. It a combination with a liquid carrier is desirable, a soft gelatin capsule is filled with a slurry of the novel compounds in soya bean or peanut oil or with an aqueous suspension or solution thereof.

The blood sugar reducing activities of some of the new antidiabetic compounds are compiled in the table below together with the activities of three known antidiabetic compounds, two of which have a substituent in the N position containing hetero-atoms.

The blood sugar reducing activity was measured intravenously in the rabbit, determining in each case the socalled threshold dose, i.e., the smallest dose of a com- 4 pound which just produced a significant blood sugar reduction. The threshold dose of BZ-SS (Nadis'an, N =sulfanilyl-N -(n-butyl)-urea) amounts in this experimental procedure to 2-00 rug/kg. In the data the values given are relative values in relation to BZ-SS: 1.

The novel thiapyranylurea derivatives are thus superior to N -(p-toluenesulfonyl)-N -(n-butyl)-urea in the tests. This is especially true in connection with N -p-methoxybenzenesulfonyl -N (tetrahydrothiapyranyl-4 urea and N -(p-toluenesulfonyl) N -(tetrahydrothiapyranyl 4)- urea. The latter two compounds are four times as effective intravenously than the comparison compound. In connection with the latter two compounds, the toxicities are also slighter than that of N p-toluenesulfonyl)-N -(n:butylurea) (Orinase) so that a greater therapeutic range is made possible. It should also be noted that in a similar experimental arrangement but where the compound was administered per os N -(p-toluenesulfonyl)-N -,tetrahydrothiapyranyl-4)-urea was ten times more effective than N -(p-toluencsulfonyl) -N -(n-butyl-urea) (Orinase) On the other hand, the alkylmercaptoalkyl compounds N -(p-toluenesulfonyD-N (3 methylmercaptopropyl)- urea and N -(p toluenesulfonyl)N (3 ethylmercaptopropyl)urea disclosed in German Patent No. 1,011,413 are less toxic than N -(p-toluenesulfonyl)-N -(n-buty1-urea) (Orinase) but are substantially inferior in antidiabetic activity to N -(p-toluenesu-1fonyl) N (n butyl urea) (Orinase) The fact that the new thiapyrane derivatives are simultaneously very effective and less toxic can therefore be characterized as very surprising.

We claim:

1. A compound selected from the group consisting of compounds of the formula:

R2 and the salts thereof with a pharmaceutically acceptable base wherein each of R and R is selected [from the group consisting of hydrogen, halogen, methyl, isopropyl, acetyl, methoxy, acetamido, azido, cyano, trifluoromethyl and amino.

2. A compound according to claim 1 designated N -(p-methoxy benzene sulfonyl) N (tetrahydrothiapyranyl-4) -urea.

3. A compound according to claim 1 designated N -(p-toluenesulfonyl)-N -(tetrahydro thiapyranyl 4)- urea.

4. A compound according to claim 1 designated N p-chloro benzenesulfonyl) N (tetrahydrothiapyranyl) -4 -urea.

5. A compound according to claim 1 designated N -(4-chloro-3-acetamino-benzenesulfonyl) N (tetrahydro-thiapyranyl-4)-urea.

6. A compound according to claim 1 designated N -(3-amino-4-chlorobenzenesulfonyl) N (tetrahydrothiapyranyl-4 -urea.

7. A compound according to claim 1 designated N -p-isopropyl-benzenesulfonyl) -N (tetrahydro thiapy-ranyl-4) -urea.

6 8. A compound according to claim 1 in the form of its FOREIGN PATENTS sodlum or Potassmm Salt 797,474 7/1953- Great Britain.

9. A compound according to claim 1 designated N -(p-acetyhbenzenesulfonyl) N (tetrahydro thiapy- OTHER REFERENCES ranyl-4)-urea. 5 Marshall et al. J. Medicinal and Pharmaceutical Chem,

References Cited vol. 6 (1963), pp. 60-3.

UNITED STATES PATENTS JAMES A. PATTEN, Primary Examiner. 2,953,578 9/1960 Haack et a1. 260347.2 3,100,208 8/1963 Haack et a1. 260--347.2 

